Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Latest Annual Report

2021 Annual Report

View Annual Report

Stock Information


Nasdaq: ADIL




52 week Low/High

Day Low/High

Company Overview

Adial Pharmaceuticals, Inc. ("the Company") is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder ("AUD") using its lead investigational new drug product, AD04, a selective serotonin-3 antagonist (i.e., a "5-HT3 antagonist"). The active ingredient in AD04 is ondansetron, the active ingredient in Zofran®, an approved drug for treating nausea and emesis. AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption. AD04 is currently being investigated in a Phase 3 clinical for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. The Company believes this approach is unique in that it targets the serotonin system and individualizes the treatment of AUD, through the use of genetic screening. The Company has created an investigational companion diagnostic biomarker test for the genetic screening of patients with certain biomarkers that, as reported in the American Journal of Psychiatry (Johnson, et. al. 2011 & 2013), are believed will benefit from treatment with AD04. The Company's strategy is to integrate the pre-treatment genetic screening into AD04's label to create a patient-specific treatment in one integrated therapeutic offering. The Company's goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of treatment.

Investor Contact Information


Adial Pharmaceutical, Inc.
1180 Seminole Trail
Ste 495
Charlottesville, VA 22901

Investor Relations

Crescendo Communications, LLC
David Waldman
5 Penn Plaza
Suite 1953
New York, NY 10001
T: 212-671-1021

Transfer Agent

VStock Transfer, LLC
Pasquale Preziosa
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436